A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

CompletadoFase 3ClinicalTrials.gov

ID: NCT01241591Tipo: INTERVENTIONALInicio: 1 de nov de 2010Fin estimado: 1 de ene de 2013

Traducción no disponible, mostrando original

Resumen

To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris);
Have plaque-type psoriasis covering at least 10% of total body surface area
Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis

Criterios de exclusión

Cannot discontinue phototherapy
Non-plaque or drug induced forms of psoriasis
Cannot discontinue current systemic and/or topical therapies for the treatment of psoriasis
Any uncontrolled significant medical condition

Intervenciones

drug

CP 690,550 5 mg

CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

drug

CP 690,550 10 mg

CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

biological

Etanercept 50 mg

Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks

other

Placebo

Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.

Ubicaciones

Centro de Investigaciones Dermatologicas

Buenos Aires, C1114aap, Argentina

Centro de Investigaciones Dermatologicas

Buenos Aires, Argentina

IMAI (Instituto Medico de Asistencia e Investigaciones)

Buenos Aires, Argentina

Patrocinadores

PrincipalPfizer

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 3, Multi Site, Randomized, Double Blind, Placebo ... | EligiMed